NCT06656390 2026-03-06
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2 Recruiting
Shanghai Allink Biotherapeutics Co., Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Cancer Commons
Singapore General Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Suzhou Transcenta Therapeutics Co., Ltd.